for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

SurModics, Inc.

SRDX.O

Latest Trade

44.29USD

Change

-1.73(-3.76%)

Volume

25,124

Today's Range

44.29

 - 

45.84

52 Week Range

38.06

 - 

68.84

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Surmodics Completes Enrollment in Pivotal TRANSCEND Clinical Trial

Aug 28 (Reuters) - Surmodics Inc <SRDX.O>::SURMODICS COMPLETES ENROLLMENT IN PIVOTAL TRANSCEND CLINICAL TRIAL.SURMODICS INC - COMPANY RAISES 2019 REVENUE AND EPS GUIDANCE.SURMODICS INC - EXPECTS FISCAL 2019 REVENUE TO BE IN A RANGE OF $97.0 MILLION TO $99.0 MILLION.SURMODICS INC - EXPECTS FISCAL 2019 EPS GUIDANCE TO A RANGE OF $0.52 TO $0.60 PER SHARE.SURMODICS INC - EXPECTS FISCAL 2019 NON-GAAP EPS TO BE IN RANGE OF $0.69 TO $0.77 PER SHARE.SURMODICS - UPON REGULATORY APPROVAL OF DEVICE, CO WILL BE RESPONSIBLE FOR MANUFACTURING CLINICAL AND COMMERCIAL QUANTITIES OF PRODUCT.SURMODICS - UPON REGULATORY APPROVAL OF DEVICE, CO TO REALIZE REVENUE FROM PRODUCT SALES TO ABBOTT, SHARE OF PROFITS RESULTING FROM SALES TO 3RD PARTIES.

Surmodics Reports Q3 GAAP Earnings Per Share Of $0.11

July 31 (Reuters) - Surmodics Inc <SRDX.O>::SURMODICS REPORTS THIRD QUARTER FISCAL 2019 RESULTS AND RAISES FISCAL 2019 REVENUE AND EPS GUIDANCE.Q3 NON-GAAP EARNINGS PER SHARE $0.15.Q3 GAAP EARNINGS PER SHARE $0.11.Q3 REVENUE $24.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $22.3 MILLION.SEES FY 2019 NON-GAAP EARNINGS PER SHARE $0.41 TO $0.49.SEES FY 2019 REVENUE $92 MILLION TO $94 MILLION.RAISES FY 2019 GAAP EARNINGS PER SHARE VIEW TO $0.24 TO $0.32.Q3 EARNINGS PER SHARE ESTIMATE $0.05 -- REFINITIV IBES DATA.

Surmodics Q2 GAAP Earnings Per Share $0.09

May 1 (Reuters) - Surmodics Inc <SRDX.O>::SURMODICS REPORTS SECOND QUARTER FISCAL 2019 RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $0.07.Q2 GAAP EARNINGS PER SHARE $0.09.Q2 REVENUE $22.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $22 MILLION.SEES FY 2019 NON-GAAP EARNINGS PER SHARE $0.26 TO $0.36.RAISES FY 2019 GAAP EARNINGS PER SHARE VIEW TO $0.14 TO $0.24.Q2 EARNINGS PER SHARE ESTIMATE $-0.02 -- REFINITIV IBES DATA.LOWERING OUR FISCAL 2019 REVENUE EXPECTATIONS BY $5.5 MILLION TO A RANGE OF $88.5 MILLION TO $91.5 MILLION.

Surmodics Sublime Guide Sheath Receives FDA 510(K) Approval

April 23 (Reuters) - Surmodics Inc <SRDX.O>::SURMODICS SUBLIME™ GUIDE SHEATH RECEIVES FDA 510(K) APPROVAL.

Surmodics Resumes Patient Enrollment In TRANSCEND Clinical Trial

April 17 (Reuters) - Surmodics Inc <SRDX.O>::SURMODICS PROVIDES UPDATE REGARDING TRANSCEND CLINICAL TRIAL.SAYS RESUMED PATIENT ENROLLMENT INTO ITS TRANSCEND CLINICAL TRIAL AND IS NEARLY 75 PERCENT OF WAY TO ITS GOAL OF 446 RANDOMIZED PATIENTS.SAYS FOLLOWING PUBLICATION OF MARCH 15 FDA COMMUNICATION, WE REACHED OUT TO AGENCY SEEKING GUIDANCE ON RECOMMENDATIONS, IMPACT ON TRANSCEND.SAYS TAKEN ACTIONS IN RESPONSE TO FDA'S RECOMMENDATIONS, INCLUDING UPDATES TO INVESTIGATOR COMMUNICATIONS, PATIENT INFORMED CONSENT FORMS.SAYS CONTINUES TO ASSESS IMPACT OF MARCH 15 FDA COMMUNICATION ON EXPECTATIONS ON TIMING OF COMPLETION OF PATIENT ENROLLMENT IN TRANSCEND TRIAL.SAYS NUMBER OF TRIAL SITES HAVE SECURED IRB OR ETHICS COMMITTEE APPROVAL OF UPDATED ICF AND ARE ACTIVELY ENROLLING, RANDOMIZING PATIENTS.SAYS TAKEN ACTIONS IN RESPONSE TO FDA'S RECOMMENDATIONS, INCLUDING UPDATES TO DATA SAFETY REVIEW AND PATIENT FOLLOW-UP PROCEDURES.

Surmodics Appoints Timothy Arens As CFO

Feb 18 (Reuters) - Surmodics Inc <SRDX.O>::SURMODICS ANNOUNCES APPOINTMENT OF TIMOTHY J. ARENS AS CHIEF FINANCIAL OFFICER.APPOINTMENT OF TIMOTHY ARENS, AS CFO EFFECTIVE IMMEDIATELY.

Surmodics Reports Q1 Non-GAAP EPS Of $0.12

Jan 30 (Reuters) - Surmodics Inc <SRDX.O>::SURMODICS REPORTS FIRST QUARTER FISCAL 2019 RESULTS.SEES FY 2019 GAAP LOSS PER SHARE $0.02 TO $0.22.Q1 NON-GAAP EARNINGS PER SHARE $0.12.Q1 GAAP EARNINGS PER SHARE $0.09.Q1 REVENUE $22.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $20.2 MILLION.SEES FY 2019 NON-GAAP EARNINGS PER SHARE $0.02 TO $0.22.SEES FY 2019 REVENUE $94 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.00 -- REFINITIV IBES DATA.UPDATING FISCAL 2019 REVENUE AND EPS GUIDANCE.

Surmodics Q4 Loss Per Share $0.13

Nov 9 (Reuters) - Surmodics Inc <SRDX.O>::SURMODICS REPORTS FOURTH QUARTER FISCAL 2018 RESULTS AND ISSUES FISCAL 2019 GUIDANCE.Q4 NON-GAAP EARNINGS PER SHARE $0.05.Q4 GAAP LOSS PER SHARE $0.13.Q4 REVENUE $23 MILLION VERSUS I/B/E/S VIEW $21.6 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.03 -- THOMSON REUTERS I/B/E/S.SEES FY 2019 GAAP LOSS PER SHARE $0.02 TO $0.32.SEES FY 2019 REVENUE $92 MILLION TO $97 MILLION.

Surmodics Q3 GAAP Loss Per Share $0.20

Aug 6 (Reuters) - Surmodics Inc <SRDX.O>::SURMODICS REPORTS THIRD QUARTER FISCAL 2018 RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $0.27.Q3 GAAP LOSS PER SHARE $0.20.SEES FY 2018 REVENUE $79 MILLION TO $81 MILLION.Q3 REVENUE $22.2 MILLION VERSUS I/B/E/S VIEW $19.4 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 NON-GAAP EARNINGS PER SHARE $0.39 TO $0.44.SEES FY 2018 LOSS PER SHARE $0.25 TO $0.30.RAISES FISCAL 2018 REVENUE GUIDANCE.

Surmodics IVD Launches Breakthrough Matrixguard Diluent

July 31 (Reuters) - Surmodics Inc <SRDX.O>::SURMODICS IVD LAUNCHES BREAKTHROUGH MATRIXGUARD™ DILUENT.SURMODICS INC - ANNOUNCED LAUNCH AND IMMEDIATE AVAILABILITY OF MATRIXGUARD DILUENT.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up